Real-world experience from the UK


Study of adult patients with severe AD with recorded outcomes between 1 and 4 months after beginning treatment with DUPIXENT at a tertiary eczema clinic2

SOUTHAMPTON: 29 patients, reviews at 1 and 4 months following DUPIXENT2

  • Mean EASI score and proportion of patients achieving EASI-50 and EASI-752

    At 4 months, a mean EASI score of 6.4 was achieved by 20 patients on DUPIXENT, compared to a mean EASI score of 19.5 at baseline2

    At 4 months, 45% of patients on DUPIXENT had achieved a >75% improvement in lesion extent and severity (EASI-75)2

      A review of 29 patients with severe atopic dermatitis at a tertiary eczema clinic. EASI and DLQI outcomes were recorded between at one and four months following beginning treatment with DUPIXENT.2 The patients had received an average of two previous systemic treatments (excluding courses of oral steroid) including ciclosporin (n=21), azathioprine (n=14), methotrexate (n=17) and mycophenolate mofetil (n=7).2

  • Mean DLQI score and proportion of patients achieving ≥4-point improvement in DLQI2

    At 4 months, a mean DLQI score of 5.3 was achieved by 20 patients on DUPIXENT, compared to a mean DLQI score of 17.8 at baseline2

    At 4 months, 85% of patients on DUPIXENT had achieved a ≥4-point improvement in DLQI2

      A review of 29 patients with severe atopic dermatitis at a tertiary eczema clinic. EASI and DLQI outcomes were recorded between at one and four months following beginning treatment with DUPIXENT.2 The patients had received an average of two previous systemic treatments (excluding courses of oral steroid) including ciclosporin (n=21), azathioprine (n=14), methotrexate (n=17) and mycophenolate mofetil (n=7).2

Baseline characteristics


 

SOUTHAMPTON2
(N=29)

Mean EASI

19.5

Mean DLQI

17.8

DUPIXENT safety profile in the Southampton2


No patients in the 4-month study required the withdrawal of treatment due to side-effects2

No abnormal results required termination of therapy2

  • DISCONTINUATION

    n (%)

    Total discontinuation, due to lack of clinical benefit

    2 (7%)

     

    AEs

    n (%)

    Conjunctivitis

    14 (48%)

    Cutaneous herpes simplex

    1 (3%)

    Axillary abscess

    1 (3%)

    Subjective hair thinning

    1 (3%)

    Signs of androgenetic alopecia

    1 (3%)

  •  

    n (%)

    Mild rise in alanine aminotransferase

    4 (14%)

    Mild eosinophilia

    4 (14%)

    Mild neutrophilia

    1 (3%)


Efficacy

Want to know how DUPIXENT can help your patients? Find out more about the Phase 3 clinical trials of DUPIXENT.




Find out more


Safety Profile

Learn more about safety profile of DUPIXENT.






Find out more


Dosing

Learn more about how to administer DUPIXENT.






Find out more

    *An EASI score is based on a clinician’s weighted score (0 to 72) of four affected areas grading the physical signs of AD (erythema, oedema/papulation, excoriation, lichenification).3–7
    The DLQI score is based on a 10-item patient questionnaire that assesses six different aspects that may affect quality of life. These aspects are symptoms and feelings, daily activities, leisure, work and school performance, personal relationships, and treatment. Each question is scored from 0 (not at all) to 3 (very much) and then totalled for the final score.3,4

    AD, atopic dermatitis; AE, adverse effect; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; UK, United Kingdom.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. O’Driscoll D, et al. Dupilumab, an incoming treatment for adolescents with atopic dermatitis: experience from a tertiary eczema. Abstract PA01. Presented at the 99th British Association of Dermatologists Annual meeting, Liverpool, July 2–4 2019.
    3. © NICE [2018] Dupilumab for treating moderate to severe atopic dermatitis. Available at: https://www.nice.org.uk/guidance/TA534/chapter/1-Recommendations. Date accessed: December 2021. All rights reserved. Subject to notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
    4. Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul. Appendix 5, Validity of Outcomes Measures. Available at: https://www.ncbi.nlm.nih.gov/books/NBK539234/. Date accessed: December 2021.
    5. EASI User Guide. HOME – Harmonising Outcome Measures for Eczema website. Available at: http://www.homeforeczema.org/documents/easi-user-guide-dec-2016-v2.pdf. Date accessed: December 2021.
    6. Leshem YA, et al. Br J Dermatol. 2015;172(5):1353–1357.
    7. Fattah D, et al. Chair’s presentation. Dupilumab for treating moderate to severe atopic dermatitis (ID1048) presented at the 2nd Appraisal Committee meeting lead team presentation, May 10 2018.

MAT-IE-2101031(v4.0) | Date of preparation: February 2022